The Post reported some experts and physicians are worried the infusion services will be “useless” against omicron while others are relieved to have access to treatments again.
Jeanne Marrazzo, MD, director of infectious diseases at the University of Alabama at Birmingham, told the Post the current situation is a “transition period,” leaving many patients confused. Dr. Marrazzo said most hospitals lack the capacity to do real-time sequencing to determine how to treat individual patients who may be infected with different variants.
Health systems across the country have been reporting shortages of the treatments since mid-December, after initial, limited shipments were paused, with some facilities suspending administration altogether until supplies replenished.
The New York Times reported Dec. 21 two of the three monoclonal antibody treatments don’t appear to be effective against the omicron variant. Preliminary data from GlaxoSmithKline, the producer of sotrovimab, shows the variant only slightly weakens the treatment’s effectiveness.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.